CRE RESPOND Forum 2024

The CRE RESPOND Forum was held to share our latest updates and developments in reducing antimicrobial resistance through optimised dosing.

Over the past two and a half years, our team, together with PhD students, has actively collaborated with centres and hospitals worldwide to continue our activity around optimised antimicrobial use. 

This forum presented some of our most recent exciting data and we hope that it will provide a springboard from which to plan for future innovations in clinical practice in infectious disease.

Program
1–1:30pm Arrivals and light lunch

1:30pm AEST Session 1: Translating research into practice
Chair: Professor Jason Roberts, Director, UQCCR and CRE RESPOND, Brisbane, Australia 

Topics

• Importance of antibiotic dosing for optimising health outcomes, Dr Lowell Ling, The Chinese University of Hong Kong
  
   

• Meeting the needs of the community through consumer involvement in infectious diseases research, Jacinta Smith
  
   

• Importance of partner design in projects, Dr Natasha Roberts, UQCCR
  
   

• How literature informs antimicrobial dosage recommendations in Therapeutic Guidelines: Antibiotic, Lisa Waddell, Therapeutic Guidelines Limited
  
   

• How literature informs international treatment guidelines, Professor Jan De Waele, Ghent University Hospital, Belgium
  
   

• The Beta-Lactam InfusioN Group (BLING): a bench to bedside to policy,  Professor Jeff Lipman, Dr Hafiz Abdul Aziz, CRE RESPOND
  
   

• RBWH Foundation, Simone Garske
  
   

3:20pm AEST Session 2: Preclinical studies and clinical pharmacokinetics
Chair: Professor Jan De Waele, Ghent University Hospital, Belgium

Topics

• In vitro infection models, Associate Professor Cornelia Landersdorfer, Monash University 
  
   

• Experimental models for preclinical studies of clinical pharmacokinetics, Associate Professor Jayesh Dhanani, Royal Brisbane and Women’s Hospital 
  
   

• OPAT stability studies, Professor Mark Gilchrist, Imperial College Healthcare NHS Trust, UK 

   

• Subcutaneous antibiotic dosing, Associate Professor Laurens Manning, The University of Western Australia 
  
   

• Screening Anti-Fungal Exposure in Intensive Care Units (SAFE-ICU study), Dr Patty Mitre, UQCCR 
  
   

• Analgesic, Sedative and Antibiotic Pharmacokinetics during Extra Corporeal Membrane Oxygenation (ASAP-ECMO), Dr Hafiz Abdul Aziz, UQCCR 
  
   

• Antibiotic Exposure at site of orthopaedic device-related infections (M-DRIFT), Professor Andrej Trampuz, Jamieson Trauma Institute 
  
   

• An investigation of the utility of microsampling versus traditional blood sampling for antibiotic pharmacokinetics in children (PIMS), Dr Suzanne Parker, UQCCR 
  
   

• PT in Pelvic Exenteration, Xin Liu, UQCCR 
  
   

4:40pm AEST Session 3: Translating dosing into practice change and regulation 
Chair:  Professor Jason Roberts

Topics

• Optimising treatment outcomes for children and adults through rapid genome sequencing of sepsis pathogens (DIRECT), Dr Adam Irwin, UQCCR 
   
   

• Resistant-Optimised Antimicrobial Dosing in Critically Ill Patients (The ROAD study), Dr Aaron Heffernan, UQCCR 
  
   

• Study of the Safety, Tolerability, Pharmacokinetics of Oral QPX2015 in Healthy Adult Subjects (QPEX Biopharma Inc.), Dr Patty Mitre, UQCCR 
  
   

• The British Society for Antimicrobial Chemotherapy (BSAC) OPAT (CAZ AVI), Saiyuri Naicker, UQCCR 
   
   

• PhaRmAcoGenoMics for better treatment of fungAl infecTions In Cancer (PRAGMATIC trial), Dr Midori Nakagaki and Dr Natasha Roberts, UQCCR 
  
   

• BLING panel discussion with refreshments: Moderated by Dr Hafiz Abdul-Aziz, with the following panel: Professor Jeffrey Lipman, Associate Professor Joel Dulhunty, Dr Elissa Milford, Professor Jan De Waele

6:15pm AEST Forum concludes

Thank you to our sponsors: